BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Berentsen S. Cold agglutinin disease. Hematology Am Soc Hematol Educ Program 2016;2016:226-31. [PMID: 27913484 DOI: 10.1182/asheducation-2016.1.226] [Cited by in Crossref: 40] [Cited by in F6Publishing: 31] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Graber ML, Berg D, Jerde W, Kibort P, Olson APJ, Parkash V. Learning from tragedy: the Julia Berg story. Diagnosis (Berl) 2018;5:257-66. [PMID: 30427778 DOI: 10.1515/dx-2018-0067] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
2 Jain NA, Zhao S, Wei L, Rogers KA, Otterson GA, Wang TF, Owen DH. Association Between RBC Antigen Allo-Antibodies and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Treatment for Advanced Cancers. Cancer Manag Res 2020;12:11743-9. [PMID: 33235503 DOI: 10.2147/CMAR.S264166] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Padmanabhan A, Connelly-Smith L, Aqui N, Balogun RA, Klingel R, Meyer E, Pham HP, Schneiderman J, Witt V, Wu Y, Zantek ND, Dunbar NM, Schwartz GEJ. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. J Clin Apher. 2019;34:171-354. [PMID: 31180581 DOI: 10.1002/jca.21705] [Cited by in Crossref: 314] [Cited by in F6Publishing: 277] [Article Influence: 104.7] [Reference Citation Analysis]
4 Ahmed Y, Khandelwal A, Walker L. Cold agglutinin disease and COVID-19 requiring therapeutic plasma exchange. BMJ Case Rep 2021;14:e244227. [PMID: 34312140 DOI: 10.1136/bcr-2021-244227] [Reference Citation Analysis]
5 Berentsen S. Neutrophil aggregation on the peripheral blood smear in a patient with cold agglutinin disease. Ann Hematol 2017;96:1767-8. [PMID: 28752395 DOI: 10.1007/s00277-017-3077-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
6 De La Puerta R, Carpio N, Sanz G, Solves P. A case of megaloblastic anemia simulating a cold autoimmune hemolytic anemia. Immunohematology 2020;36:89-92. [DOI: 10.21307/immunohematology-2020-046] [Reference Citation Analysis]
7 Maslov DV, Simenson V, Jain S, Badari A. COVID-19 and Cold Agglutinin Hemolytic Anemia. TH Open 2020;4:e175-7. [PMID: 32844144 DOI: 10.1055/s-0040-1715791] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
8 Kamesaki T, Nishimura J, Wada H, Yu E, Tsao E, Morales J, Kanakura Y. Demographic characteristics, thromboembolism risk, and treatment patterns for patients with cold agglutinin disease in Japan. Int J Hematol 2020;112:307-15. [DOI: 10.1007/s12185-020-02899-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Yeşilbaş O. Current treatment options for severe autoimmune hemolytic anemia. Turk Pediatri Ars 2018;53:129-30. [PMID: 30116136 DOI: 10.5152/TurkPediatriArs.2018.6499] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
10 Dawudi Y, Federici L, Debus J, Zucman N. Cold agglutinin disease secondary to severe SARS-CoV-2 treated with eculizumab. BMJ Case Rep 2022;15:e242937. [PMID: 35487646 DOI: 10.1136/bcr-2021-242937] [Reference Citation Analysis]
11 Berentsen S. New Insights in the Pathogenesis and Therapy of Cold Agglutinin-Mediated Autoimmune Hemolytic Anemia. Front Immunol 2020;11:590. [PMID: 32318071 DOI: 10.3389/fimmu.2020.00590] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 10.0] [Reference Citation Analysis]
12 Nyssen A, Benhadou F, Magnée M, André J, Koopmansch C, Wautrecht JC. Chilblains. Vasa 2020;49:133-40. [PMID: 31808732 DOI: 10.1024/0301-1526/a000838] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
13 Li Y, Clow F, Fraser JD, Lin F. Therapeutic potential of staphylococcal superantigen-like protein 7 for complement-mediated hemolysis. J Mol Med (Berl) 2018;96:965-74. [PMID: 30066197 DOI: 10.1007/s00109-018-1678-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
14 Berentsen S, Randen U, Oksman M, Birgens H, Tvedt THA, Dalgaard J, Galteland E, Haukås E, Brudevold R, Sørbø JH, Næss IA, Malecka A, Tjønnfjord GE. Bendamustine plus rituximab for chronic cold agglutinin disease: results of a Nordic prospective multicenter trial. Blood 2017;130:537-41. [DOI: 10.1182/blood-2017-04-778175] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 9.8] [Reference Citation Analysis]
15 Röth A, Bommer M, Hüttmann A, Herich-Terhürne D, Kuklik N, Rekowski J, Lenz V, Schrezenmeier H, Dührsen U. Eculizumab in cold agglutinin disease (DECADE): an open-label, prospective, bicentric, nonrandomized phase 2 trial. Blood Adv 2018;2:2543-9. [PMID: 30291112 DOI: 10.1182/bloodadvances.2018024190] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 10.0] [Reference Citation Analysis]
16 Le Clef Q, Menter T, Tzankov A. Our approach to bone marrow biopsies in cytopenia. Pathol Res Pract 2019;215:152447. [PMID: 31101575 DOI: 10.1016/j.prp.2019.152447] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
17 Bylsma LC, Gulbech Ording A, Rosenthal A, Öztürk B, Fryzek JP, Arias JM, Röth A, Berentsen S. Occurrence, thromboembolic risk, and mortality in Danish patients with cold agglutinin disease. Blood Adv 2019;3:2980-5. [PMID: 31648316 DOI: 10.1182/bloodadvances.2019000476] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
18 Jacobs J, Pogue E, Johnson M, Eichbaum Q. Passenger lymphocyte syndrome with severe haemolysis misdiagnosed/treated as cold agglutinin syndrome: Analysis of case and diagnostic error. Transfus Med 2021;31:305-7. [PMID: 33821519 DOI: 10.1111/tme.12773] [Reference Citation Analysis]
19 Rossi G, Gramegna D, Paoloni F, Fattizzo B, Binda F, D’adda M, Farina M, Lucchini E, Mauro FR, Salvi F, Marchetti M, Fazi P, Zaja F, Barcellini W. Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective GIMEMA study. Blood 2018;132:547-50. [DOI: 10.1182/blood-2018-03-835413] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 8.0] [Reference Citation Analysis]
20 Laursen NS, Pedersen DV, Gytz H, Zarantonello A, Bernth Jensen JM, Hansen AG, Thiel S, Andersen GR. Functional and Structural Characterization of a Potent C1q Inhibitor Targeting the Classical Pathway of the Complement System. Front Immunol 2020;11:1504. [PMID: 32849513 DOI: 10.3389/fimmu.2020.01504] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Jäger U, Barcellini W, Broome CM, Gertz MA, Hill A, Hill QA, Jilma B, Kuter DJ, Michel M, Montillo M, Röth A, Zeerleder SS, Berentsen S. Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting. Blood Rev 2020;41:100648. [PMID: 31839434 DOI: 10.1016/j.blre.2019.100648] [Cited by in Crossref: 55] [Cited by in F6Publishing: 55] [Article Influence: 18.3] [Reference Citation Analysis]
22 La Gioia A, Fumi M, Fiorini F, Pezzati P, Balboni F, Bombara M, Marini A, Pancione Y, Solarino L, Marchese E, Sale S, Rocco V, Fiorini M. Short preheating at 41°C leads to a red blood cells count comparable to that in RET channel of Sysmex analysers in samples showing cold agglutination. J Clin Pathol 2018;71:729-34. [PMID: 29535214 DOI: 10.1136/jclinpath-2017-204954] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
23 Sefland Ø, Randen U, Berentsen S. Development of Multiple Myeloma of the IgA Type in a Patient with Cold Agglutinin Disease: Transformation or Coincidence? Case Rep Hematol 2019;2019:1610632. [PMID: 30949369 DOI: 10.1155/2019/1610632] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
24 Murakhovskaya I. Rituximab Use in Warm and Cold Autoimmune Hemolytic Anemia. J Clin Med 2020;9:E4034. [PMID: 33322221 DOI: 10.3390/jcm9124034] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
25 Röth A, Fryzek J, Jiang X, Reichert H, Patel P, Su J, Morales Arias J, Broome CM. Complement-mediated hemolysis persists year round in patients with cold agglutinin disease. Transfusion 2021. [PMID: 34813663 DOI: 10.1111/trf.16745] [Reference Citation Analysis]
26 Gabbard AP, Booth GS. Cold Agglutinin Disease. Clin Hematol Int 2020;2:95-100. [PMID: 34595449 DOI: 10.2991/chi.k.200706.001] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
27 Jäger U, D'Sa S, Schörgenhofer C, Bartko J, Derhaschnig U, Sillaber C, Jilma-Stohlawetz P, Fillitz M, Schenk T, Patou G, Panicker S, Parry GC, Gilbert JC, Jilma B. Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial. Blood 2019;133:893-901. [PMID: 30559259 DOI: 10.1182/blood-2018-06-856930] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 9.8] [Reference Citation Analysis]
28 Berentsen S. Complement Activation and Inhibition in Autoimmune Hemolytic Anemia: Focus on Cold Agglutinin Disease. Semin Hematol 2018;55:141-9. [PMID: 30032751 DOI: 10.1053/j.seminhematol.2018.04.002] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
29 Vágó EK, Nicholson G, Horváth-Puhó E, Hooda N, Fryzek JP, Su J. Healthcare resource utilization among patients with cold agglutinin disease in Denmark. Curr Med Res Opin 2021;:1-7. [PMID: 34308723 DOI: 10.1080/03007995.2021.1960494] [Reference Citation Analysis]
30 Gelbenegger G, Schoergenhofer C, Derhaschnig U, Buchtele N, Sillaber C, Fillitz M, Schenk TM, D'Sa S, Cartwright R, Gilbert JC, Jilma B, Jaeger U. Inhibition of complement C1s in patients with cold agglutinin disease: lessons learned from a named patient program. Blood Adv 2020;4:997-1005. [PMID: 32176765 DOI: 10.1182/bloodadvances.2019001321] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
31 Tedeschi A, Conticello C, Rizzi R, Benevolo G, Laurenti L, Petrucci MT, Zaja F, Varettoni M. Diagnostic framing of IgM monoclonal gammopathy: Focus on Waldenström macroglobulinemia. Hematological Oncology 2019;37:117-28. [DOI: 10.1002/hon.2539] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
32 Su J, Bylsma LC, Jiang X, Morales Arias J, Jain N, Nordyke RJ. Healthcare resource utilization among commercially insured patients with cold agglutinin disease in the United States. Journal of Medical Economics 2020;23:902-7. [DOI: 10.1080/13696998.2020.1764006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
33 Boutboul D, Touzot F, Szalat R. Understanding therapeutic emergencies in acute hemolysis. Intensive Care Med 2018;44:482-5. [PMID: 28871399 DOI: 10.1007/s00134-017-4918-6] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
34 Joly F, Schmitt LA, Watson PAM, Pain E, Testa D. The Burden of Cold Agglutinin Disease on Patients’ Daily Life: An Online Survey of 50 American Patients (Preprint). JMIR Formative Research. [DOI: 10.2196/34248] [Reference Citation Analysis]
35 Kaur J, Mogulla S, Khan R, Krishnamoorthy G, Garg S. Transient Cold Agglutinins in a Patient With COVID-19. Cureus 2021;13:e12751. [PMID: 33643726 DOI: 10.7759/cureus.12751] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
36 Keragala CB, Draxler DF, McQuilten ZK, Medcalf RL. Haemostasis and innate immunity - a complementary relationship: A review of the intricate relationship between coagulation and complement pathways. Br J Haematol 2018;180:782-98. [PMID: 29265338 DOI: 10.1111/bjh.15062] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 9.2] [Reference Citation Analysis]